Abstract: In the present study, the ORF5M gene (the modified ORF5 gene) and ORF6 gene，the two major immunogenicity genes of PRRSV, were used as the target genes, and bovine herpesvirus 1(BHV-1 )VP22 possessing protein transduction property was chosed as the immunoadjuvant. Based on homologous recombination，a recombinant PRV (rPRV) TK^-/gE^-/VP22E⁺/VP22M⁺ coexpressing PRRSV E and M protein fused with BHV-1 VP22 protein was constructed by using PRV TK^-/gE^-/LacZ⁺ as parent strain. The rPRV was confirmed by PCR, Southern blot and Western blot. The results of TCID₅₀ tests showed that the insertion of the foreign genes had no influence on the propagation of rPRV in IBRS-2 or PK-15 cells. BALB/c mice were immunized with rPRV TK^-/gE^-/VP22E⁺/VP22M⁺, and compared with rPRV TK^-/gE^-/E⁺ expressing ORF5M gene and TK^-/gE^-/E⁺/M⁺ coexpressing ORF5M and ORF6 genes respectively. Neutralizing antibodies and lymphocyte proliferative responses were evaluated at 10 weeks after primary immunization. Among three rPRVs，TK^-/gE^-/VP22E⁺/VP22M⁺ had the best effect on enhancing PRRSV-specific humoral and cellular immune responses, and VP22 showed adjuvant efficiencies on rPRV vaccine to a certain degree. In conclusion, the study established a base for the research of bivalent genetic engineering vaccines against PRRSV and PRV.